CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab

The use of biological therapy is now common practice in the treatment of immune-mediated inflammatory diseases (IMID). Currently, there are no guidelines related to the management of cytomegalovirus (CMV) infections or reactivation during therapy with biological agents. Furthermore, there is a lack...

Descripción completa

Detalles Bibliográficos
Autores principales: Gambardella, Alessio, Licata, Gaetano, Calabrese, Giulia, De Rosa, Alina, Pagliuca, Francesca, Alfano, Roberto, Argenziano, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711202/
https://www.ncbi.nlm.nih.gov/pubmed/33282718
http://dx.doi.org/10.2147/PTT.S284701
_version_ 1783618097840652288
author Gambardella, Alessio
Licata, Gaetano
Calabrese, Giulia
De Rosa, Alina
Pagliuca, Francesca
Alfano, Roberto
Argenziano, Giuseppe
author_facet Gambardella, Alessio
Licata, Gaetano
Calabrese, Giulia
De Rosa, Alina
Pagliuca, Francesca
Alfano, Roberto
Argenziano, Giuseppe
author_sort Gambardella, Alessio
collection PubMed
description The use of biological therapy is now common practice in the treatment of immune-mediated inflammatory diseases (IMID). Currently, there are no guidelines related to the management of cytomegalovirus (CMV) infections or reactivation during therapy with biological agents. Furthermore, there is a lack of guidance on the management of asymptomatic patients with persistent positive immunoglobulin (Ig)M anti-CMV after an extended period and who have to undergo therapy with biological agents. We report the case of a patient in this situation for whom treatment with biological drugs for psoriasis was indicated. A good clinical response was obtained with secukinumab and maintained during 6 months of follow-up. No infectious disease or reactivation of CMV infection occurred. We suggest some possible guidelines for the management of such cases.
format Online
Article
Text
id pubmed-7711202
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77112022020-12-03 CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab Gambardella, Alessio Licata, Gaetano Calabrese, Giulia De Rosa, Alina Pagliuca, Francesca Alfano, Roberto Argenziano, Giuseppe Psoriasis (Auckl) Case Report The use of biological therapy is now common practice in the treatment of immune-mediated inflammatory diseases (IMID). Currently, there are no guidelines related to the management of cytomegalovirus (CMV) infections or reactivation during therapy with biological agents. Furthermore, there is a lack of guidance on the management of asymptomatic patients with persistent positive immunoglobulin (Ig)M anti-CMV after an extended period and who have to undergo therapy with biological agents. We report the case of a patient in this situation for whom treatment with biological drugs for psoriasis was indicated. A good clinical response was obtained with secukinumab and maintained during 6 months of follow-up. No infectious disease or reactivation of CMV infection occurred. We suggest some possible guidelines for the management of such cases. Dove 2020-11-27 /pmc/articles/PMC7711202/ /pubmed/33282718 http://dx.doi.org/10.2147/PTT.S284701 Text en © 2020 Gambardella et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Gambardella, Alessio
Licata, Gaetano
Calabrese, Giulia
De Rosa, Alina
Pagliuca, Francesca
Alfano, Roberto
Argenziano, Giuseppe
CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab
title CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab
title_full CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab
title_fullStr CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab
title_full_unstemmed CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab
title_short CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab
title_sort cmv infection: a clinical challenge in biological therapy? the case of asymptomatic patients with persistent positive immunoglobulin m anti-cmv treated with secukinumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711202/
https://www.ncbi.nlm.nih.gov/pubmed/33282718
http://dx.doi.org/10.2147/PTT.S284701
work_keys_str_mv AT gambardellaalessio cmvinfectionaclinicalchallengeinbiologicaltherapythecaseofasymptomaticpatientswithpersistentpositiveimmunoglobulinmanticmvtreatedwithsecukinumab
AT licatagaetano cmvinfectionaclinicalchallengeinbiologicaltherapythecaseofasymptomaticpatientswithpersistentpositiveimmunoglobulinmanticmvtreatedwithsecukinumab
AT calabresegiulia cmvinfectionaclinicalchallengeinbiologicaltherapythecaseofasymptomaticpatientswithpersistentpositiveimmunoglobulinmanticmvtreatedwithsecukinumab
AT derosaalina cmvinfectionaclinicalchallengeinbiologicaltherapythecaseofasymptomaticpatientswithpersistentpositiveimmunoglobulinmanticmvtreatedwithsecukinumab
AT pagliucafrancesca cmvinfectionaclinicalchallengeinbiologicaltherapythecaseofasymptomaticpatientswithpersistentpositiveimmunoglobulinmanticmvtreatedwithsecukinumab
AT alfanoroberto cmvinfectionaclinicalchallengeinbiologicaltherapythecaseofasymptomaticpatientswithpersistentpositiveimmunoglobulinmanticmvtreatedwithsecukinumab
AT argenzianogiuseppe cmvinfectionaclinicalchallengeinbiologicaltherapythecaseofasymptomaticpatientswithpersistentpositiveimmunoglobulinmanticmvtreatedwithsecukinumab

Ejemplares similares